HIV Medicine最新文献

{"title":"Sustained effect of Scotland's HIV pre-exposure prophylaxis programme on transmission among gay and bisexual men who have sex with men: Population-based retrospective cohort study","authors":"Alan Yeung,&nbsp;Claudia Estcourt,&nbsp;Beth Cullen,&nbsp;Rebecca Metcalfe,&nbsp;Alison Rodger,&nbsp;Dan Clutterbuck,&nbsp;Nicola Steedman,&nbsp;Rak Nandwani,&nbsp;Duncan McCormick,&nbsp;Sharon Hutchinson","doi":"10.1111/hiv.70255","DOIUrl":"10.1111/hiv.70255","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the population-level impact of seven years of Scotland's HIV pre-exposure prophylaxis (PrEP) programme among gay, bisexual and other men who have sex with men (GBMSM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>National administrative data were used to estimate PrEP coverage and HIV incidence among 35 342 GBMSM attending specialist sexual health services between July 2015 and March 2024. Poisson regression was used to investigate the risk of HIV acquisition and its association with the extent of PrEP prescribing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>PrEP coverage increased from 21% in the initial PrEP period (July 2017 to March 2020) to 45% in the latter period (April 2022 to March 2024). HIV incidence reduced from 4.46 per 1000 person-years in the pre-PrEP period (July 2015 to June 2017) to 1.66 in the initial PrEP period (aIRR 0.37, 95% CI 0.25–0.54) and remained stable thereafter. During the entire PrEP period, the risk of HIV acquisition was reduced among those ‘currently prescribed’ (involving 4 HIV acquisitions among 11 720 person-years) compared to those never prescribed (60 HIV acquisitions among 34 328 person-years) (aIRR 0.19, 95% CI 0.07–0.51). Compared to those currently prescribed PrEP, risk was greatest in those prescribed 12+ months ago (11 HIV acquisitions among 3824 person-years) (aIRR 8.13, 95% CI 2.58–25.64).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>HIV incidence was sustained at a low level as PrEP coverage broadened among GBMSM, but did not reduce further. Efforts to support persistence and re-engagement with PrEP are warranted in those at ongoing risk of HIV.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"27 8","pages":"1298-1311"},"PeriodicalIF":3.2,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70255","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Models of care for women living with HIV in Europe: A scoping review","authors":"D. Rao,&nbsp;O. M. Inescu,&nbsp;C. A. Sabin,&nbsp;O. Sǎndulescu,&nbsp;G. Dragovic,&nbsp;Å. Mellgren,&nbsp;J. Kowalska,&nbsp;G. Lourida,&nbsp;E. Moseholm,&nbsp;EACS WAVE Health Care Perception Working Group","doi":"10.1111/hiv.70266","DOIUrl":"10.1111/hiv.70266","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>With the widespread availability of antiretroviral therapy, human immunodeficiency virus (HIV) has become a chronic condition requiring long-term, integrated care. Women with HIV experience distinct clinical, reproductive, and psychosocial needs shaped by gender and social determinants. However, care models addressing these needs for women in Europe have not been comprehensively documented. In this scoping review, we aim to map existing literature on models of care for women with HIV in Europe and examine their key components and regional variation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We searched the Ovid database to identify studies on care models for women with HIV in Europe from 2000 onwards. We further included national guidelines provided by the European AIDS Clinical Society (EACS) country representatives. Two reviewers independently extracted data and synthesized findings using descriptive content analysis informed by the World Health Organization Social Determinants of Health framework.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Out of 8183 records screened, 17 studies and guidelines met inclusion criteria. Most originated from Western and Central Europe, with only one source from Eastern Europe. We identified 10 core components of women-responsive HIV services: co-design of services with women with HIV, healthcare provider training, tailored programming for women, gender-inclusive and culturally sensitive approaches, HIV/AIDS continuum of care, multidisciplinary integration of services, emotional and psychological support services, peer-support programmes, social support services and gender-specific HIV research. These components collectively addressed clinical management, psychosocial well-being and structural determinants influencing engagement and retention in care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Effective HIV care for women in Europe requires integrated, life-course-oriented models beyond virological control, addressing psychosocial and structural determinants, while expanding women-centred services, particularly in Eastern Europe.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"27 8","pages":"1212-1224"},"PeriodicalIF":3.2,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148163063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality trends for diabetes mellitus, hypertension and cardiovascular disease among people living with and without HIV in Brazil during the COVID-19 pandemic, 2020–2022","authors":"Tatyellen Natasha da Costa Oliveira,&nbsp;Rodrigo C. Moreira,&nbsp;Luiz Max Carvalho,&nbsp;Flávio Codeço Coelho,&nbsp;Marcelo Ferreira da Costa Gomes,&nbsp;Leonardo S. Bastos,&nbsp;Laís Picinini Freitas,&nbsp;Antonio G. Pacheco","doi":"10.1111/hiv.70240","DOIUrl":"10.1111/hiv.70240","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>People living with HIV (PLWH) face an increasing burden of non-AIDS-related chronic conditions. However, how the COVID-19 pandemic affected chronic disease-related mortality in this population remains unclear. We assessed changes in mortality among PLWH in Brazil during the COVID-19 pandemic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a nationwide analysis using Brazil's Mortality Information System, including adults aged ≥18 years with and without HIV mentioned on death certificates from 2016 to 2022. Age- and sex-adjusted mortality ratios (aMRs) were estimated for all-cause mortality and for deaths associated with diabetes mellitus (DM), hypertension (HTN) and cardiovascular disease (CVD) using Poisson generalized linear mixed models, with the pre-pandemic period 2016–2019 used as the reference.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Between 2016 and 2022, 90 888 deaths occurred among PLWH and 9 723 490 among individuals without HIV. Among PLWH, adjusted all-cause mortality ratios were lower in 2020 (aMR 0.918; 95% CI 0.900–0.936) and 2022 (aMR 0.950; 95% CI 0.932–0.968), while estimates for 2021 were close to the reference period. In contrast, individuals without HIV experienced increased mortality in 2020 (aMR 1.106; 95% CI 1.104–1.108), 2021 (aMR 1.269; 95% CI 1.267–1.272) and 2022 (aMR 1.029; 95% CI 1.027–1.031). Among PLWH, mortality associated with DM (aMRs 1.573–1.666), HTN (aMRs 1.738–1.978) and CVD (aMRs 1.242–1.377) increased consistently across all pandemic years. Among individuals without HIV, chronic disease-related mortality showed greater temporal variability, with increases in 2020 and 2021 followed by reductions in 2022.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Chronic disease-related mortality increased persistently among PLWH during the COVID-19 pandemic, contrasting with declining trends in the general population. These results emphasize distinct mortality dynamics among PLWH during public health crises.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"27 8","pages":"1265-1276"},"PeriodicalIF":3.2,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70240","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147633197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hodgkin and non-Hodgkin lymphomas in the post-antiretroviral therapy era according to HIV virological suppression","authors":"Teresa Aldámiz-Echevarria,&nbsp;Francisco Tejerina,&nbsp;Chiara Fanciulli,&nbsp;Cristina Diez,&nbsp;Leire Perez,&nbsp;José Maria Bellón,&nbsp;Nuria Espinosa,&nbsp;Santiago Moreno Guillén,&nbsp;Maria del Mar Arcos-Rueda,&nbsp;Marta Montero-Alonso,&nbsp;Lucio García-Fraile,&nbsp;Victor Asensi,&nbsp;Marian Fernández López,&nbsp;Diana Corona-Mata,&nbsp;Alfonso Cabello-Úbeda,&nbsp;Meritxell Gavaldà Manso,&nbsp;Jose Antonio Iribarren,&nbsp;Laura Pérez-Martínez,&nbsp;María Remedios Alemán Valls,&nbsp;Irene Portilla-Tamarit,&nbsp;Joaquim Peraire,&nbsp;Inés Suárez-García,&nbsp;Mar Masiá,&nbsp;María José Núñez Orantos,&nbsp;Ángela Gutiérrez Liarte,&nbsp;Arkaitz Imaz,&nbsp;Cristina Hernández Gutiérrez,&nbsp;Maria Tasias Pitarch,&nbsp;Marta Rava,&nbsp;CoRIS Cohort","doi":"10.1111/hiv.70257","DOIUrl":"10.1111/hiv.70257","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Lymphomas remain among the most frequent HIV-associated malignancies, with risk persisting despite effective virological control.</p>\u0000 \u0000 <p>This study describes the clinical, epidemiological and prognostic characteristics of lymphomas (both Hodgkin [HL] and non-Hodgkin [NHL]) in people living with HIV (PLWH), according to virological suppression at diagnosis and assesses lymphoma-related mortality at 1 year and overall survival at 5 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a multicentre retrospective study including PLWH from the Spanish CoRIS cohort, who were diagnosed with lymphoma between 2004 and 2022 and had HIV viral load data at diagnosis. Virological suppression was defined as HIV-1 RNA &lt;100 copies/mL within the 6 months prior to and 1 month following lymphoma diagnosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 18 573 PLWH included in CoRIS, 291 developed lymphoma, with virological data available for 245 individuals, of whom 49 (20%) had virological suppression. People with detectable HIV viral load had lower CD4 counts (median 180 cells/mm³ [IQR 80–330] vs. 371 cells/mm³ [IQR 202–583], <i>p</i> &lt; 0.001) and more advanced Ann Arbor stage (stage III–IV: 82.0% vs. 64.1%, <i>p</i> = 0.027) compared with those with virological suppression. Despite this, they showed similar treatment response (complete remission: 67.1% vs. 76.2%) and relapse rates (16.3% vs. 18.4%, <i>p</i> = 0.779). Furthermore, virological suppression was not independently associated with 1-year lymphoma-specific or 5-year overall survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In PLWH diagnosed with lymphoma, prognosis is independent of HIV virological status at diagnosis. These findings support that lymphoma management in PLWH should be guided by standard oncological criteria, alongside antiretroviral therapy, regardless of HIV viral suppression status.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"27 8","pages":"1312-1332"},"PeriodicalIF":3.2,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70257","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147963357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Legal status, sex work engagement and inequities in the HIV pre-exposure prophylaxis cascade among migrant women in 11 European countries","authors":"Haoyi Wang,&nbsp;Anne Flaherty-Gupta,&nbsp;Hala Majdoub,&nbsp;Edwin Sesange,&nbsp;Kim Isip,&nbsp;Justine Lubnow,&nbsp;Pedro Barrios Sanchez,&nbsp;Linda Pavanello,&nbsp;Etinosa Erevbenagie-Johnbull,&nbsp;Lillian Petry,&nbsp;Emma Gooding,&nbsp;Magdalena Ankiersztejn-Bartczak,&nbsp;Stavroula Triantafyllidou,&nbsp;Ann Piercy,&nbsp;Kai J. Jonas,&nbsp;Denis Onyango,&nbsp;Hanne M. L. Zimmermann,&nbsp;the MiHealth HIV Partnership","doi":"10.1111/hiv.70259","DOIUrl":"10.1111/hiv.70259","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Migrant women account for a substantial proportion of new HIV diagnoses in Europe, yet remain underrepresented in HIV prevention research. Little is known about how legal status and national policy context shape engagement with PrEP among migrant women, particularly those without secure documentation. We assessed the PrEP cascade and HIV prevention preferences among migrant women, examining how legal status, sex work engagement and national reimbursement policies drive inequities in access.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a community-led, cross-sectional survey (June–July 2025) of 521 HIV-negative migrant women recruited offline via community-based organisations. Multivariable logistic regression examined associations between legal status, sex work, country-level PrEP reimbursement policies and PrEP cascade outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 521 participants, 259 (49.7%) lacked secure legal status (119 asylum seekers, 89 refugees and 51 undocumented migrants) and 90 (17.3%) were engaged in sex work. Overall, 40.1% (95% CI 35.9–44.5) were aware of PrEP and 24.6% (20.9–28.6) intended to use it, yet only 6.0% (4.1–8.4) were current users; 36.7% (23.8–51.7) of PrEP-experienced women had discontinued use. Compared with naturalised citizens or documented residents, undocumented migrants (aOR = 2.57, 95% CI = 1.19–5.64), asylum seekers (3.67, 1.98–6.93) and refugees (2.28, 1.22–4.31) had higher odds of PrEP awareness. Sex workers had higher odds of current PrEP use (5.50, 1.61–20.42). Residing in countries with full PrEP reimbursement was independently associated with higher uptake (4.96, 1.30–26.11). Although condoms were the most preferred method (60.3%), interest in daily oral and long-acting injectable PrEP was evident, particularly among undocumented women and sex workers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A four-fold gap between PrEP intention and actual uptake among migrant women reflects a failure of universal health coverage, driven by restrictive migration governance and health financing. Achieving HIV equity requires decoupling PrEP eligibility from documentation status and expanding community-led delivery.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"27 8","pages":"1344-1357"},"PeriodicalIF":3.2,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70259","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147972108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to ‘Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system’","authors":"","doi":"10.1111/hiv.70274","DOIUrl":"10.1111/hiv.70274","url":null,"abstract":"<p>\u0000 <span>Zhang, L</span>, <span>Chen, L</span>, <span>Tang, J</span>, et al. <span>Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system</span>. <i>HIV Med.</i> <span>2026</span>; <span>27</span>(<span>5</span>): <span>749</span>–<span>760</span>. doi:10.1111/hiv.70205\u0000 </p><p>In the version of this article initially published, the funding information was incomplete. The correct version is as follows:</p><p>The author(s) declare that financial support was received for the research and/or publication of this article. This study was funded by the Special Research Fund for the Central High-level Hospitals of Peking Union Medical College Hospital (2022-PUMCH-D-008), the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2021-I2M-1-037), the National Key Technologies R&amp;D Program for the 13th Five-year Plan (2017ZX10202101-001), the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS) (2025-12M-XHZY-002) and the Peking Union Medical College Hospital Talent Cultivation Program (Category A) (ULJ03044).</p><p>We apologize for this error.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"27 8","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70274","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148338474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An overview of consent requirements for HIV and viral hepatitis B and C testing in Europe","authors":"Annemarie Rinder Stengaard,&nbsp;Ann K. Sullivan,&nbsp;Daniel Simões,&nbsp;Josephine Diderichsen,&nbsp;Dorthe Raben,&nbsp;Jürgen K. Rockstroh,&nbsp;the EuroTEST Steering Committee","doi":"10.1111/hiv.70248","DOIUrl":"10.1111/hiv.70248","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Complicated consent procedures for bloodborne virus (HIV, HBV and HCV) testing present barriers to implementation, particularly in non-specialist healthcare settings. European and global guidelines no longer recommend written consent. An overview of testing consent requirements in Europe is lacking.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>An online survey on legal and policy frameworks and implementation/practice was developed by a working group under the EuroTEST Initiative and disseminated to clinical and community-based testing facilities and national public health institutions and/or HIV/hepatitis organizations/societies in the countries of the WHO European Region. Data collection and validation occurred between October 2023 and April 2024. Responses were validated via email and/or bilateral discussions if diverging across same-country respondents to obtain one answer per country.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Findings</h3>\u0000 \u0000 <p>A total of 84 responses from 36 community-based testing sites, 33 healthcare facilities and 15 public health institutes in 34 countries were included. Written or documented verbal consent remained a policy requirement for HIV testing in 12 countries (4/18 western, 6/11 central, 2/5 eastern). For viral hepatitis, opt-out testing was much more common and written/documented verbal consent a policy requirement in five countries only. Practices for how consent is obtained in reality varied by setting and did not always follow legal/policy requirements.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>Written/documented consent remains a requirement for HIV testing in more than a third of responding countries. Removing the need for written/documented verbal consent and expanding opt-out testing will reduce testing barriers, reduce HIV exceptionalism, align national requirements with global standards and support European countries in reaching the first UNAIDS 95–95–95 target of 95% of those infected, diagnosed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"27 8","pages":"1253-1264"},"PeriodicalIF":3.2,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70248","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Migration-related inequalities in HIV diagnosis, treatment initiation and retention in care among migrants in Greece.","authors":"Nikos Pantazis, Varvara Vasalou, Olga Tsachouridou, Vasileios Papastamopoulos, Konstantinos Protopapas, Myrto Astriti, Maria Chini, Mina Psichogiou, Georgios Chrysos, Nikolaos V Sipsas, Helen Sambatakou, Markos Marangos, Diamantis Kofteridis, Periklis Panagopoulos, Giota Touloumi","doi":"10.1111/hiv.70294","DOIUrl":"https://doi.org/10.1111/hiv.70294","url":null,"abstract":"<p><strong>Objectives: </strong>Migrants account for a substantial proportion of people living with HIV in Europe, yet inequalities across the HIV care continuum remain insufficiently characterized. We examined migration-related differences in HIV diagnosis, treatment initiation and retention in care in Greece.</p><p><strong>Methods: </strong>We analyzed data from the Athens Multicenter AIDS Cohort Study (AMACS), including individuals diagnosed with HIV between 1996 and 2024. Participants were classified by region of origin. Markers of HIV diagnosis (CD4 cell count, late presentation, advanced disease and time from seroconversion to diagnosis) and post-diagnosis outcomes (time to antiretroviral therapy [ART] initiation and loss to follow-up [LTFU]) were evaluated using appropriate regression and flexible parametric survival models.</p><p><strong>Results: </strong>Among 11 467 individuals, 19.3% were migrants. Migrants presented with more advanced disease, including higher rates of late presentation (71.0% among those from Africa vs. 48.9% among Greek-born) and longer diagnostic delays (median 4.8 vs. 3.1 years, respectively). Over time, differences in late presentation narrowed, although advanced disease and diagnostic delay remained higher among some groups. Time to ART initiation decreased substantially with attenuated differences between groups after adjustment for CD4 levels at diagnosis. In contrast, recorded LTFU in AMACS increased over time and remained higher among migrants, reaching 49% within 3 years among individuals from Africa compared with 12% among Greek-born.</p><p><strong>Conclusions: </strong>Inequalities in HIV care outcomes across region-of-origin groups in Greece persist but have shifted along the care continuum. While timely ART initiation has largely equalized, disparities remain in delayed diagnosis and recorded follow-up. Targeted strategies to mitigate observed inequalities are essential.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal cancer screening uptake and lesion detection in people living with HIV: A systematic review and meta-analysis.","authors":"Motoki Kaneko, Atsushi Sakuraba","doi":"10.1111/hiv.70288","DOIUrl":"10.1111/hiv.70288","url":null,"abstract":"<p><strong>Introduction: </strong>As people living with HIV age, the absolute colorectal cancer (CRC) burden rises, yet the extent of routine CRC screening delivery and clinical yield is unclear. We synthesized evidence on screening uptake and lesion detection in people living with HIV, including comparisons with HIV-negative controls.</p><p><strong>Methods: </strong>We searched PubMed, EMBASE and Cochrane CENTRAL through 8 November 2025. We included antiretroviral therapy-era studies of adults with HIV (mean/median age ≥50 years) reporting CRC screening uptake in routine care or pathology-confirmed lesions at screening lower endoscopy (colonoscopy/sigmoidoscopy). Random-effects restricted maximum likelihood (REML) meta-analyses pooled single-arm proportions and comparative risk ratios; sensitivity, influence and cumulative analyses were prespecified.</p><p><strong>Results: </strong>Twenty-two studies were included. For screening uptake, 15 studies (people living with HIV n = 29 469) contributed single-arm estimates and 6 studies (people living with HIV n = 26 001; controls n = 858 658) contributed comparative data. Pooled uptake of screening among people living with HIV was 43% (95% confidence interval [CI] 36%-50%). Pooled detection of adenoma, villous/tubulovillous adenoma and CRC by screening lower endoscopy in people living with HIV was 27%, 3.8% and 1.4%, respectively. Screening uptake and lesion detection rates showed no significant difference from controls, though study numbers were limited and heterogeneous.</p><p><strong>Conclusion: </strong>In people living with HIV, CRC prevention is constrained by low and variable screening uptake. Screening lower endoscopy identifies clinically significant lesions, highlighting the need to improve CRC screening delivery in this population.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the impact, barriers and facilitators of peer-driven interventions on the prevention of mother-to-child transmission of HIV in low- and middle-income countries: A systematic review and meta-analysis.","authors":"Victor Oluwafemi Femi-Lawal, Rhoda Fadairo, Joshua Alabi, Christian Tague, Mubarak Mustapha, Chukwuebuka Asogwa, Emmanuel Agboke, Oluwatimilehin Oladapo, Emmanuel Ngwu, Gideon Olajide, Daniel Esanju, John Ibeh, Temidayo Lawrence, Ismail Abdullahi, Marvellous Jesujevwe","doi":"10.1111/hiv.70285","DOIUrl":"https://doi.org/10.1111/hiv.70285","url":null,"abstract":"<p><strong>Introduction: </strong>Peer interventions may improve retention across the prevention of mother-to-child transmission (PMTCT) cascade in low- and middle-income countries (LMICs), where poor adherence to antiretroviral therapy (ART) remains a major barrier. This systematic review and meta-analysis evaluated the impact of peer support interventions on PMTCT outcomes to inform scalable strategies.</p><p><strong>Methods: </strong>Following PRISMA guidelines, we searched PubMed, Cochrane Library, Scopus and Google Scholar (2008-2025) using terms including 'peer mentors,' 'PMTCT' and 'LMICs.' Independent reviewers conducted data extraction and quality appraisal using Cochrane risk-of-bias tools. Random-effects meta-analysis was performed in R (v4.4.3), with significance set at p < 0.05. Qualitative findings were thematically synthesized.</p><p><strong>Results: </strong>Twenty-seven studies (n = 26 431) across 10 countries were included. Peer interventions improved ART adherence at one year (OR: 1.19, 95% CI: 1.05-1.35) and two years (OR: 2.04, 95% CI: 1.58-2.64), PMTCT retention at six weeks postpartum (OR: 2.63, 95% CI: 1.56-4.43), infant uptake of HIV prophylaxis (OR: 2.95, 95% CI: 1.90-4.59), early infant diagnosis (OR: 1.64, 95% CI: 1.01-2.67) and viral load testing (OR: 1.21, 95% CI: 1.07-1.38). No significant effects were observed for ART initiation, PMTCT retention at 12 months or HIV status disclosure. Most studies (75%) reported improved exclusive breastfeeding. Barriers included stigma, inadequate mentor training, logistical and economic constraints and poor male involvement; facilitators included training, incentives and community trust.</p><p><strong>Conclusion: </strong>Peer interventions improve adherence, infant prophylaxis and retention but have limited effects on viral suppression and disclosure. Addressing stigma, strengthening health systems and enhancing male engagement may optimize impact.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148535768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}